JT
BCAX

Jupiter Topco’s Bicara Therapeutics BCAX Stock Holding History

Jupiter Topco’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94M Buy
+3,171,015
New +$70.8M 0.04% 325

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jupiter Topco's BCAX Position: Q2 2026 in Review

Jupiter Topco opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 3,171,015 shares worth $94M. The stake represents 0.04% of the portfolio and ranks #325 among its holdings.

157 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Jupiter Topco held 3,171,015 shares of Bicara Therapeutics worth $94M as of Q2 2026.
  • Bicara Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Bicara Therapeutics made up 0.04% of Jupiter Topco's portfolio in Q2 2026, its #325 holding.
  • 157 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.